



ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences

February 1, 2023

WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 1, 2023-- [ImmunoGen, Inc.](https://www.immunogen.com) (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:

- **Guggenheim Healthcare Talks 2023 Oncology Conference**

February 9 at 3:20pm ET

- **SVB Securities Global Biopharma Conference**

February 15 at 10:00am ET

A webcast of each presentation will be accessible through the "Investors and Media" section of the Company's website, www.immunogen.com. Following the live webcast, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230201005203/en/): <https://www.businesswire.com/news/home/20230201005203/en/>

INVESTOR RELATIONS

ImmunoGen
Anabel Chan
781-895-0600
anabel.chan@immunogen.com

MEDIA

ImmunoGen
Courtney O'Konek
781-895-0600
courtney.okonek@immunogen.com

OR

FTI Consulting
Robert Stanislaro
212-850-5657
robert.stanislaro@fticonsulting.com

Source: ImmunoGen, Inc.